A Study of the Safety and Efficacy of AGN-214868 in Patients With Postherpetic Neuralgia

Completed · Phase 2 · Has a placebo group

Conditions studied: Neuralgia, Postherpetic

In brief

This study will evaluate the safety and efficacy of AGN-214868 in patients with postherpetic neuralgia (PHN) - nerve pain.

Key facts

Study ID

NCT01129531

Run by

Allergan

People needed

294

Starts

2010-06-01

Expected to finish

2012-01-01

Last updated by the study team

2013-11-15

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Persistent postherpetic neuralgia (PHN) with nerve pain present for at least 9 months after onset of herpes zoster skin rash

You may not qualify if…

• Female patients with reproductive potential
• Active herpes zoster skin rash
• Current or anticipated treatment with acupuncture, TNS, or steroids
• Current or anticipated use of topical analgesic agents with PHN
• Treatment with botulinum toxin therapy of any serotype within the prior 12 weeks

Where it is running

• Study site — Orlando, Florida, United States
• Study site — Brno, Czechia
• Study site — Kiel, Kiel, Germany
• Study site — Katowice, Poland

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.